miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 10, 2025

Stock market today: S&P 500, Nasdaq soar, lead Dow higher as Senate vote lifts hopes for end to US shutdown

View original at finance.yahoo.com
Stock market today: S&P 500, Nasdaq soar, lead Dow higher as Senate vote lifts hopes for end to US shutdown Tech stocks led a roaring start to Wall Street's week, with investor spirits boosted by Congress taking a big step toward ending the record-breaking government shutdown that has clouded the picture of the economy…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • North American exports of LNG are expected to more than double over the same period

    80% confidence

  • The extraordinary list of accomplishments achieved in the past few months tells the story of Venture Global's unwavering commitment to streamline high-impact execution in its growth to date

    80% confidence

  • US capacity for natural gas liquefaction is expected to more than double by 2029

    80% confidence

  • There are clear signs an earnings recovery is underway that will fuel a stock rally next year

    80% confidence

  • A lot of liquidity pulled out of the market since August peaks, sentiment soured, and government shutdown brought malaise that turned market tenderness into vulnerability

    80% confidence

  • S&P 500 will reach 7,500 by the end of 2026, fueled by strong corporate earnings and gains in resilient technology sector

    80% confidence

Citado en estos reportajes de Via News

Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Stock market today: S&P 500, Nasdaq soar, lead Dow higher as Senate vote lifts hopes for end to US shutdown — Source | Via News | es.VIA.NEWS